Not legal or compliance advice: This article is educational only. It does not constitute legal, regulatory, or compliance advice. Before acting on any idea described here, consult your legal counsel, your 340B compliance officer, your external auditor, the HRSA Office of Pharmacy Affairs (OPA), and Apexus. Program rules evolve; always verify current guidance against HRSA and Apexus sources at the time you make a decision.
Business development inside a 340B covered entity is fundamentally different from business development in a commercial pharmacy or device company. The program exists, in the words of the 1992 Senate report accompanying the statute, to help covered entities "stretch scarce Federal resources as far as possible, reaching more eligible patients and providing more comprehensive services." That phrase is not a marketing slogan — it is the lens through which every decision, every site addition, every contract pharmacy relationship, and every internal metric should be examined.
A well-built roadmap translates that mission into a disciplined, multi-year plan that is compliance-first, patient-first, and only then growth-oriented. This article walks through what business development means in the 340B context, how to govern it, and how to sequence it.
In commercial settings, business development is typically a hunt for revenue, margin, and market share. In a covered entity, the phrase must be reframed. The underlying program asset is not a product you sell; it is an access mechanism that allows you to serve more patients, deepen services, and reinvest in mission. If a roadmap is designed around maximizing a financial return rather than strengthening access and stewardship, it will drift — often invisibly — into posture that an auditor or the HRSA OPA would find difficult to defend.
Reframed this way, 340B business development has three jobs:
Language matters: Internally, retire phrases like "340B revenue," "340B profit," or "savings target." Prefer "program stewardship," "net program benefit reinvested in mission," or "eligible patient reach." Language influences behavior, and behavior influences audit posture.
Every covered entity has both a mission statement and a set of statutory obligations under Section 340B of the Public Health Service Act (42 U.S.C. § 256b). The roadmap should start from the intersection of the two.
A useful exercise for a planning retreat is to write — on one page — the answers to these four questions:
If any of those answers is fuzzy, the roadmap is not yet ready to move to tactics. Those four answers are also the frame you will return to whenever a tempting opportunity arrives that does not quite fit.
A 340B roadmap without an owner is a wish list. Governance should be deliberately layered.
This is the operational nerve center. It typically includes the 340B program director or coordinator, pharmacy leadership, clinic or outpatient operations leadership, finance, compliance, revenue cycle, information technology, and a representative from the split-billing or TPA function. The committee's remit is to review day-to-day program operations, monitor key indicators, approve policies and procedures, and evaluate any proposed changes (new sites, new contract pharmacies, new drug categories) against compliance risk.
Most often the CFO, COO, or Chief Pharmacy Officer, the sponsor is accountable to the CEO and board for the program's health. The sponsor's job is to ensure the compliance committee has authority, budget, and access to legal counsel, and to escalate risks upward before they become material findings.
The board should receive, at minimum, an annual briefing on 340B program scope, material risks, audit activity, and mission reinvestment. Some boards establish a compliance subcommittee that reviews 340B alongside other regulated programs. The board is not meant to run the program, but it is meant to know enough to ask hard questions.
A simple governance test: If your 340B coordinator resigned tomorrow, would your board know within 30 days? Would legal counsel? Would your external auditor? If not, governance is too thin.
Most covered entities benefit from thinking in three sequential phases. The phases are not calendar-bound — a mature program may cycle through "stabilize" repeatedly after a system migration or leadership change — but they should be done in order.
Before anything else, ensure the current program is defensible. That means:
Until this list is solid, new growth typically amplifies existing weaknesses rather than adding value.
Once stabilized, look inward. Optimization is about doing the existing program better, not bigger. Examples:
Only after stabilization and optimization should expansion appear on the roadmap. Expansion may include registering additional child sites, adding contract pharmacies in geographies that serve your eligible population, or extending services (e.g., specialty pharmacy) where patient need is clear. Expansion decisions should be evaluated individually against compliance risk, operational readiness, and mission alignment.
A roadmap is easier to build when you can see everything on one page. Build an inventory — spreadsheet, internal wiki, or diagram — that captures eligible sites, provider types, patient population, pharmacy partners, technology stack, and named people. This map becomes the foundation for everything else — stakeholder analysis, risk register, and phase planning.
Stakeholder mapping is an often-skipped step that pays back many times over. For each major decision, identify who must approve, who must be consulted, who must be informed, and who is responsible for execution. Keeping this map current turns "surprise" stakeholder objections into predictable checkpoints.
Every covered entity should maintain a written 340B risk register. It does not need to be elaborate; a simple table reviewed quarterly by the compliance committee is enough.
Minimal risk register columns: risk description; category (eligibility, duplicate discount, diversion, data integrity, contract pharmacy oversight, workforce, vendor, regulatory change); likelihood and impact; current controls; control gaps; owner; next review date.
Registering a risk does not solve it, but it makes it visible. Most 340B audit findings trace back to risks that were known informally but never written down and assigned.
A roadmap needs measurable success criteria, but the criteria must be chosen carefully. In 340B, what you measure shapes what your staff optimize. If the only dashboard is a savings dashboard, the program will drift toward savings behavior.
Consider pairing every financial stewardship indicator with at least one non-financial indicator. Examples include percentage of eligible encounters correctly identified, data-feed completeness from each contract pharmacy, time-to-close on self-identified compliance findings, provider roster accuracy, and policy-and-procedure review currency. Stewardship indicators should be tracked, reported to the board, and told as a narrative alongside the numbers.
Avoid revenue-style targets: Setting a dollar target for "340B savings" — especially one tied to individual compensation — creates incentive misalignment that auditors and plaintiffs' attorneys have noticed. Consult legal counsel on compensation design touching 340B.
A predictable annual cycle builds discipline and makes the roadmap a living document rather than a shelf artifact. Consider reviewing prior-year self-audit results in January; completing OPAIS reconciliation in March; holding a strategic planning retreat in spring; providing a mid-year board update in June; refreshing policies and training in summer; aligning budget and mission reinvestment in fall; and closing with a year-end self-audit and board briefing. Adjust for your fiscal calendar and recertification window, but keep the cadence.
Chasing savings over compliance. When growth targets precede eligibility discipline, covered entities accumulate undiagnosed risks that surface during a HRSA audit or a manufacturer dispute.
Under-investing in infrastructure. Every new child site, contract pharmacy, or service line has an infrastructure cost — plan for it.
Skipping documentation. "We do it, we just don't write it down" is not a defense. If it is not written, it did not happen.
Treating the 340B coordinator as a single point of failure. Cross-train, document workflows, and build a deputy structure.
Ignoring evolving guidance. Build a standing agenda item for "regulatory and policy changes since last meeting" and verify current guidance with HRSA OPA and Apexus before acting.
Confusing the TPA's dashboard with the program's health. Augment TPA views with internal audits.
A 340B business development roadmap is, in the end, a compliance and access plan with financial implications — not a financial plan with compliance footnotes. Covered entities that keep that order of operations tend to weather audits, regulatory shifts, and manufacturer disputes with fewer surprises. Those that invert it tend to accumulate quiet risk until a triggering event makes the risk loud.
This article is educational and does not constitute legal, tax, regulatory, compliance, or financial advice. Program rules change; verify current guidance with HRSA's Office of Pharmacy Affairs, Apexus, and qualified counsel before acting.